Novartis AG agreed to pay $245 million to end antitrust litigation accusing the company of trying to delay the launch of generic versions of the drug Exforge in the United States.
The Consolidated Appropriations Act will increase competition from generic and biosimilar medicines and enhance patient access to lower cost prescription drugs.
The United States Court of Appeals for the Federal Circuit has granted a motion to temporarily enjoin the generic launch by Teva and Apotex of Hetlioz.